Search
Semaglutide Treatment Options
A collection of 185 research studies where Semaglutide is the interventional treatment. These studies are located in the United States. Semaglutide is used for conditions such as Diabetes Mellitus, Type 2, Obesity and Diabetes.
37 - 48 of 185
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
Featured Trial
Crohn's Disease Clinical Study
Recruiting
Help us study a potential new way to treat Crohn's disease. We are seeking adults living with Crohn's disease to join our latest clinical trial to help us learn more. Eligible participants will receive study-related treatment, assessments, and care at no cost. You will also receive reimbursement for travel while participating. Health insurance is not required to take part.
Conditions:
Crohn's Disease
Crohn Disease
Crohns Disease
Crohn's Disease (CD)
Crohn Colitis
A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes
Active Not Recruiting
This study compares 2 medicines for type 2 diabetes: semaglutide (new medicine) and a dummy medicine (placebo). Semaglutide will be tested to see how well it works compared to the dummy medicine. The study will also test if semaglutide is safe in children and teenagers. Participants will either get semaglutide or the dummy medicine - which one is decided by chance. Participants will take 1 tablet of the study medicine every morning on an empty stomach. They have to wait 30 minutes before they ea... Read More
Gender:
ALL
Ages:
Between 10 years and 18 years
Trial Updated:
05/01/2025
Locations: Children's Hospital Los Angeles - Endocrinology, Los Angeles, California +66 locations
Conditions: Diabetes Mellitus, Type 2
Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment
Recruiting
More than 40% of young adults with type 1 diabetes (T1D) also have overweight or obesity. Each of these diagnoses increase the risk of adverse cardiovascular events. GLP-1 analogues are anti-obesity medications that are cardioprotective in adults with type 2 diabetes, however evaluation of these agents in people with T1D has been limited to glycemic outcomes. Investigators aim to study the impact of GLP-1 analogue obesity treatment on markers of cardiometabolic risk in young adults with T1D and... Read More
Gender:
ALL
Ages:
Between 18 years and 30 years
Trial Updated:
04/29/2025
Locations: Yale Pediatric Diabetes Center, Adult and Children's Progam, New Haven, Connecticut
Conditions: Diabetes type1, Obesity
GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH
Recruiting
The goal of this research study is to evaluate the pathophysiologic mechanisms by which genetic variation impacts response to an FDA-approved medication commonly used to treat type 2 diabetes called oral semaglutide (Rybelsus) and to characterize the physiological response to a mixed meal tolerance test (MMTT) before and after a 14-day treatment with oral semaglutide. The investigators will do this by measuring factors in the blood, such as sugars, fats, metabolites, and proteins, after eating a... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
04/28/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Genetic Predisposition, Metabolic Diseases, Type 2 Diabetes
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)
Active Not Recruiting
This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease.
Participants will either get semaglutide or placebo (a "dummy" medicine which does not contain any study medicine) - which treatment participants get is decided by an equal chance.
The study will last for up to 173 weeks (about 3 years and 4 months). Participants will have 17 clinic visits and 1 phone call with the study doctor. The study includes various tests and scans. At 10... Read More
Gender:
ALL
Ages:
Between 55 years and 85 years
Trial Updated:
04/27/2025
Locations: Banner Alzheimer's Institute, Phoenix, Arizona +386 locations
Conditions: Early Alzheimer´s Disease
A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE)
Active Not Recruiting
This study is comparing the medicine RYBELSUS® to other medicines in people with type 2 diabetes who need extra treatment. All medicines used in this study are tablets which lower blood sugar in people with type 2 diabetes. The purpose of the study is to see how well RYBELSUS® is at lowering blood sugar compared to other tablets when used in addition to metformin. Participants doctor will give participants either RYBELSUS® or any other blood sugar lowering tablets - which treatment participants... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/27/2025
Locations: FDRC, Costa Mesa, California +21 locations
Conditions: Diabetes Mellitus, Type 2
A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)
Completed
We are doing this study to learn more about how semaglutide may help fight chronic kidney disease in people with type 2 diabetes. We are doing this by looking into how semaglutide works in the kidneys.
Participants will either get semaglutide or placebo (a 'dummy' medicine) - which treatment participants get is decided by chance.
Semaglutide is a medicine doctors can prescribe in some countries for the treatment of type 2 diabetes.
Participants will get the study medicine in a pen. Participan... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/27/2025
Locations: Academic Medical Research Institute, Los Angeles, California +30 locations
Conditions: Diabetes Mellitus, Type 2, Chronic Kidney Disease
A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)
Completed
This study compares semaglutide, together with a lower dose of insulin glargine, to a higher dose of insulin glargine in participants with type 2 diabetes. The study looks at how well the study medicines control blood glucose levels. Participants will either get semaglutide together with a lower dose of insulin glargine or a higher dose of insulin glargine. The study will last for about 47 weeks (approximately 11 months). Participants will have 9 clinic visits, 15 phone/video calls and 1 home vi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/27/2025
Locations: Valley Research, Fresno, California +109 locations
Conditions: Diabetes Mellitus, Type 2, Obesity
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
Active Not Recruiting
This study will look at the long-term effects of semaglutide (active medicine) on diabetic eye disease when compared to placebo (dummy medicine). The study will be performed in people with type 2 diabetes. Participants will either get semaglutide or placebo in addition to their diabetes medicines - which treatment the participant gets is decided by chance. Participants will inject the study medicine using a pen-injector. The medicine must be injected in a skin fold in the stomach, thigh or upper... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/27/2025
Locations: Del Sol Research Management, LLC, Tucson, Arizona +177 locations
Conditions: Diabetes Mellitus, Type 2
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)
Active Not Recruiting
This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease.
Participants will either get semaglutide or placebo (a "dummy" medicine which does not contain any study medicine) - which treatment participants get is decided by an equal chance.
The study will last for up to 173 weeks (about 3 years and 4 months). Participants will have 17 clinic visits and 1 phone call with the study doctor. The study includes various tests and scans. At 10... Read More
Gender:
ALL
Ages:
Between 55 years and 85 years
Trial Updated:
04/27/2025
Locations: Banner Alzheimer's Institute, Phoenix, Arizona +342 locations
Conditions: Early Alzheimer's Disease
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
Recruiting
The study evaluates the safety of different doses of a new medicine called NNC0519 0130. It also looks into how the medicine may improve kidney function in participants with chronic kidney disease with or without type 2 diabetes, living with overweight or obesity. The participants will either get NNC0519-0130 (a new medicine), semaglutide (a medicine that doctors can already prescribe), or placebo (a "dummy" substance). Which treatment the participant will get is decided by chance. The study wil... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/27/2025
Locations: N America Res Inst - San Dimas, San Dimas, California +121 locations
Conditions: Chronic Kidney Disease
Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.
Recruiting
This is a Phase IIb, randomised, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy, safety and tolerability of AZD5004 in adults with type 2 diabetes mellitus, compared to placebo and active comparator.
Gender:
ALL
Ages:
All
Trial Updated:
04/25/2025
Locations: Research Site, Mobile, Alabama +120 locations
Conditions: Diabetes Mellitus, Type 2
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
Active Not Recruiting
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and inadequate glycemic control with metformin with or without sodium-glucose cotransporter-2 inhibitor (SGLT2i). The study will last about 26 months and may include up to 24 visits.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: University of Alabama - Department of Nutrition Sciences, Birmingham, Alabama +76 locations
Conditions: Diabetes Mellitus, Type 2
37 - 48 of 185